• Login
    View Item 
    •   NRU
    • Journal Publications
    • Medical and Health Sciences
    • Medical and Health Sciences
    • View Item
    •   NRU
    • Journal Publications
    • Medical and Health Sciences
    • Medical and Health Sciences
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Reduced morbidity and mortality in the first year after initiating highly active anti-retroviral therapy (HAART) among Ugandan adults

    Thumbnail
    View/Open
    Article (62.38Kb)
    Date
    2009
    Author
    Miiro, George
    Todd, Jim
    Mpendo, Juliet
    Watera, Christine
    Munderi, Paula
    Nakubulwa, Susan
    Kaddu, Ismael
    Rutebarika, Diana
    Grosskurth, Heiner
    Metadata
    Show full item record
    Abstract
    To evaluate the effect of highly active anti-retroviral therapy (HAART) and cotrimoxazole prophylaxis on morbidity after HAART eligibility. methods Between 1999 and 2006, we collected morbidity data from a community-based cohort of HAART-eligible patients, comparing patients initiating HAART and those non-HAART. Patients aged 15 years or older visited the clinic every 6 months and when ill. Baseline data on patients’ characteristics, WHO stage, haemoglobin and CD4+ T-cell counts, along with follow-up data on morbidity (new, recurrent and drug-related), were collected for the first year after initiating HAART or becoming HAART-eligible. We estimated the overall effect of HAART on morbidity; adjusted for the effect of cotrimoxazole prophylaxis by Mantel–Haenszel methods. A negative binomial regression model was used to assess rate ratios (RR) after adjustment for other confounders, including cotrimoxazole. results A total of 219 HAART patients (median age 37 years; 73% women; 82% using cotrimoxazole prophylaxis, median haemoglobin 11.7 g ⁄ dl and median CD4+ 131 cells ⁄ ll) experienced 94 events in 127 person-years. 616 non-HAART patients (median age 33 years; 70% women; 26% using cotrimoxazole prophylaxis, median haemoglobin 11.2 g ⁄ dl and median CD4+ 130 cells ⁄ ll) experienced 862 events in 474 person-years. The overall morbidity during the first year of HAART was 80% lower than among non-HAART patients (adjusted RR = 0.20, 95% CI: 0.12–0.34). Cotrimoxazole prophylaxis also reduced morbidity (adjusted RR = 0.65, 95% CI: 0.45–0.94). conclusion These results confirm the reduction in morbidity due to HAART, and the additional protection of cotrimoxazole prophylaxis.
    URI
    https://nru.uncst.go.ug/handle/123456789/3251
    Collections
    • Medical and Health Sciences [2894]

    Research Dissemination Platform copyright © since 2021  UNCST
    Contact Us | Send Feedback
    Partners
     

     

    Browse

    All of NRU
    Communities & CollectionsBy Issue DateAuthorsTitlesSubjects
    This Collection
    By Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    Statistics

    View Usage Statistics

    Research Dissemination Platform copyright © since 2021  UNCST
    Contact Us | Send Feedback
    Partners